Leading researchers recently gathered at Cleveland Clinic to review promising developments in breast cancer treatment, including new drugs for HER2+ and ER+ metastatic disease and preserving fertility during chemotherapy.
Adjuvant therapies and genetics research for breast cancer dominated recent oncology meetings. Key studies, summarized by Cleveland Clinic’s Jame Abraham, MD in The ASCO Post, should lead to better treatment.
Cleveland Clinic’s multidisciplinary approach to cancer care is demonstrated in the new Tumor Board webcast video series. The series launches with an HER2-positive breast cancer case.
This 37-year-old woman’s case illustrates the value of a multidisciplinary spine tumor board when metastatic breast cancer first manifests as back pain.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
A unique trial will test the combination of two powerful and targeted breast cancer drugs, determining their safety and tolerability in Phase I and the overall response rate in Phase II.
Clinical trial compares chemotherapy schedules in high-risk early-stage breast cancer.
Researchers at Cleveland Clinic are participating in a multicenter study of CDX-011 for triple negative breast cancer.
Effective physical rehabilitation for cancer patients tailors therapy to differing needs at each stage of the disease process. Here are tips from Cleveland Clinic’s recent experience.
For a woman with breast cancer, the prospect of receiving radiation therapy in a single dose during surgery, rather than going through six weeks of radiation treatments, is a welcome one. That possibility is becoming a reality for more women with early-stage breast cancer. Intraoperative radiotherapy (IORT) applies a single dose of radiation directly to … Read More
The latest radiation therapies for treating breast cancer minimize exposure to the heart and reduce likelihood of survivors developing late cardiac complications.